SCHEMBL930388

SCHEMBL930388

CCOc1ccc(Oc2cccc(C(=O)O)c2)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 1/20 0.70
SMN1; SMN2 Q16637 2/20 0.67
TP53 P04637 1/20 0.67
PKM P14618 1/20 0.67
NFKB1 P19838 1/20 0.67
NFKB2 Q00653 1/20 0.67
RELA Q04206 1/20 0.67
MRGPRX4 Q96LA9 1/20 0.67
NPC1 O15118 2/20 0.66
RAB9A P51151 2/20 0.66
POLB P06746 1/20 0.66
CYP2C9 P11712 1/20 0.66
FABP1 P07148 2/20 0.63
LTA4H P09960 1/20 0.61
KMT2A Q03164 1/20 0.60
NR1H4 Q96RI1 1/20 0.60
MITF O75030 1/20 0.60
PAX8 Q06710 1/20 0.60
KMO O15229 1/20 0.59
KDM4E B2RXH2 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29505938 0.89 KMT2A (0.75) AKR1C3SMN1; SMN2TP53PKMNFKB1
SCHEMBL1333545 0.89 KMT2A (0.75) AKR1C3SMN1; SMN2TP53PKMNFKB1
SCHEMBL29505934 0.89 KMT2A (0.75) AKR1C3SMN1; SMN2TP53PKMNFKB1
Hydrochloric Acid SCHEMBL30608606 0.87 KMT2A (0.73) AKR1C3SMN1; SMN2TP53PKMNFKB1
SCHEMBL30266789 0.87 AKR1C3 (0.92) AKR1C3MRGPRX4NPC1RAB9APOLB
SCHEMBL1042631 0.87 AKR1C3 (0.92) AKR1C3MRGPRX4NPC1RAB9APOLB
SCHEMBL9005759 0.85 PLA2G4B (0.76) AKR1C3TP53LTA4HKMT2ANR1H4
SCHEMBL930833 0.85 MEN1 (0.62) SMN1; SMN2NPC1RAB9APOLBCYP2C9
SCHEMBL4320685 0.85 AKR1C3 (0.96) AKR1C3PKMMRGPRX4NPC1RAB9A
SCHEMBL28701196 0.85 AKR1C3 (0.96) AKR1C3PKMMRGPRX4NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120183660-A1 ISOMANNIDE DERIVATIVES AND THEIR USE AS TASTANTS SENOMYX, INC. (US) 2012-07-19 US disclosed
EP-2448944-A2 ISOMANNIDE DERIVATIVES AND THEIR USE AS TASTANTS Senomyx, Inc. (US) 2012-05-09 EP disclosed
WO-2011002871-A2 ISOMANNIDE DERIVATIVES AND THEIR USE AS TASTANTS SENOMYX, INC (US) 2011-01-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120183660-A1 ISOMANNIDE DERIVATIVES AND THEIR USE AS TASTANTS TAS2R41, TAS2R42, TAS2R40 AKR1C3 2334/4885SMN1; SMN2 3291/4885TP53 2397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.